Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
NCT01394211 · University of Arizona · PHASE2 · terminated · last registry update 2018-07-26 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, University of Arizona |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP19A1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-07-15Results posted on the registry: Novartis Pharmaceuticals, Lapatinib + Trastuzumab (NCT01160211)
- 2019-05-29Results posted on the registry: ETOP IBCSG Partners Foundation, triptorelin + degarelix (NCT02005887)
- 2019-03-12Results posted on the registry: National Cancer Institute (NCI), Anastrozole + Exemestane (NCT00310180)
- 2019-01-29Results posted on the registry: ETOP IBCSG Partners Foundation, Letrozole + Letrozole (NCT00553410)
- 2019-01-29Phase 3 first posted: ETOP IBCSG Partners Foundation, Palbociclib 125mg + Standard endocrine therapy (NCT03820830)
- 2018-12-19Phase 3 first posted: Stemline Therapeutics, Inc., Elacestrant + Standard of Care (NCT03778931)
- 2018-10-10Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib (NCT03701334)
- 2018-03-23Results posted on the registry: Eli Lilly and Company, Abemaciclib + Anastrozole (NCT02246621)
- 2018-02-20Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2018-02-08Phase 3 first posted: Borstkanker Onderzoek Groep, CDK 4/6 inhibitor + Non-Steroidal Aromatase Inhibitor (NCT03425838)
- 2018-02-06Results posted on the registry: Pfizer, Enzalutamide + exemestane (NCT02007512)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision